Yono Makoto, Yoshida Masaki, Yamamoto Yasuhiro, Imanishi Aya, Fukagawa Atsushi, Latifpour Jamshid, Eto Masatoshi
Department of Urology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan.
Life Sci. 2009 Aug 12;85(7-8):334-8. doi: 10.1016/j.lfs.2009.06.014. Epub 2009 Jul 2.
Although doxazosin, but not nifedipine, can partially prevent a decrease in urogenital expression of nitric oxide synthase (NOS) in spontaneously hypertensive rats (SHRs), the mechanisms involved in the regulated expression of NOS are not known. Therefore, we identified differential gene expression profiles in SHRs to elucidate the molecular mechanisms regulating urogenital expression of NOS.
SHRs and normotensive Wistar-Kyoto (WKY) rats received doxazosin (30 mg/kg/day) or nifedipine (30 mg/kg/day) orally for 4 weeks. Microarray expression data of key transcripts were verified by real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis.
RT-PCR data, in accord with the microarray analysis, indicated that untreated SHRs had lower mRNA expression levels of cAMP responsive element binding protein 1 (Creb1) in the pelvic ganglion and vascular endothelial growth factor A (Vegfa) and kinase insert domain protein receptor (Kdr) in the penis, and higher mRNA expression levels of brain derived neurotrophic factor and neurotrophin 3 (Ntf3) in the bladder and Ntf3, Rho-kinases (Rock1 and Rock2) and caveolin 1 (Cav1) in the penis than untreated WKY rats. In SHRs, doxazosin and nifedipine caused a significant decrease in penile expression of Rock1 and Rock2, whereas the differential alterations in urogenital expression of Creb1, Vegfa, Kdr and Cav1 were attenuated by treatment with doxazosin, but not nifedipine.
Our data suggest that differential alterations in the expression of several genes related to pathways that mediate NOS expression in the urogenital tissues of SHRs, which can be attenuated by doxazosin treatment, may play an important role in regulating urogenital expression of NOS.
虽然多沙唑嗪而非硝苯地平可部分预防自发性高血压大鼠(SHR)泌尿生殖系统一氧化氮合酶(NOS)表达的降低,但NOS表达调控的相关机制尚不清楚。因此,我们鉴定了SHR中的差异基因表达谱,以阐明调节泌尿生殖系统NOS表达的分子机制。
SHR和正常血压的Wistar-Kyoto(WKY)大鼠口服多沙唑嗪(30mg/kg/天)或硝苯地平(30mg/kg/天),持续4周。关键转录本的微阵列表达数据通过实时逆转录-聚合酶链反应(RT-PCR)分析进行验证。
RT-PCR数据与微阵列分析一致,表明未经治疗的SHR盆腔神经节中cAMP反应元件结合蛋白1(Creb1)、阴茎中血管内皮生长因子A(Vegfa)和激酶插入结构域蛋白受体(Kdr)的mRNA表达水平较低,膀胱中脑源性神经营养因子和神经营养因子3(Ntf3)以及阴茎中Ntf3、Rho激酶(Rock1和Rock2)和小窝蛋白1(Cav1)的mRNA表达水平高于未经治疗的WKY大鼠。在SHR中,多沙唑嗪和硝苯地平可使阴茎中Rock1和Rock2的表达显著降低,而Creb1、Vegfa、Kdr和Cav1泌尿生殖系统表达的差异改变可被多沙唑嗪治疗减弱,但不能被硝苯地平减弱。
我们的数据表明,与介导SHR泌尿生殖组织中NOS表达的途径相关的几个基因表达的差异改变可能在调节泌尿生殖系统NOS表达中起重要作用,多沙唑嗪治疗可减弱这些改变。